Aberdeen Group plc Purchases 519,374 Shares of Vir Biotechnology, Inc. $VIR

Aberdeen Group plc lifted its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 51.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,526,265 shares of the company’s stock after buying an additional 519,374 shares during the period. Aberdeen Group plc owned about 1.10% of Vir Biotechnology worth $8,715,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. ARCH Venture Management LLC acquired a new stake in Vir Biotechnology during the 2nd quarter worth approximately $65,100,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Vir Biotechnology in the second quarter valued at approximately $289,000. Allianz Asset Management GmbH raised its holdings in shares of Vir Biotechnology by 6.2% during the second quarter. Allianz Asset Management GmbH now owns 327,700 shares of the company’s stock worth $1,652,000 after acquiring an additional 19,000 shares during the period. Ensign Peak Advisors Inc lifted its position in Vir Biotechnology by 812.7% in the 2nd quarter. Ensign Peak Advisors Inc now owns 582,981 shares of the company’s stock valued at $2,938,000 after acquiring an additional 519,107 shares in the last quarter. Finally, Corton Capital Inc. bought a new stake in Vir Biotechnology in the 2nd quarter valued at $114,000. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Trading Down 0.1%

VIR stock opened at $7.82 on Friday. Vir Biotechnology, Inc. has a 1-year low of $4.16 and a 1-year high of $9.97. The business’s 50 day simple moving average is $6.71 and its 200 day simple moving average is $5.90. The firm has a market capitalization of $1.09 billion, a PE ratio of -2.17 and a beta of 1.69.

Insider Buying and Selling at Vir Biotechnology

In other news, Director Vicki L. Sato sold 22,000 shares of Vir Biotechnology stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $7.71, for a total transaction of $169,620.00. Following the completion of the sale, the director owned 1,144,391 shares of the company’s stock, valued at approximately $8,823,254.61. This trade represents a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Endurance (Cayman) Ltd Svf sold 235,971 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $6.38, for a total transaction of $1,505,494.98. Following the completion of the sale, the insider directly owned 14,110,209 shares of the company’s stock, valued at approximately $90,023,133.42. The trade was a 1.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 912,589 shares of company stock worth $5,711,308 in the last quarter. Company insiders own 16.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $14.00 price target on shares of Vir Biotechnology in a research note on Monday, February 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Finally, Barclays set a $26.00 price target on shares of Vir Biotechnology in a research note on Tuesday. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Vir Biotechnology currently has an average rating of “Moderate Buy” and a consensus price target of $16.29.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.